CPTx develops single-stranded DNA products to neutralize viruses and address infectious diseases.
CPTx has raised $29.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2024.
CPTx's investors include BlueYard Capital, Bayern Kapital, Leblon Capital, SPRIN-D, Marius Nacht.
CPTx is headquartered in Planegg, Germany.
CPTx develops single-stranded DNA products to neutralize viruses and address infectious diseases.
CPTx is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CPTx — Funding & Investors." VCBacked, September 12, 2024, https://www.vcbacked.co/company/cptx. Accessed July 19, 2026.
VCBacked. (2024). CPTx — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cptx
{{cite web |title=CPTx — Funding & Investors |url=https://www.vcbacked.co/company/cptx |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated